Athersys (ATHX) News Today → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free ATHX Stock Alerts $0.0050 0.00 (0.00%) (As of 03/15/2024) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)americanbankingnews.com - March 19 at 2:22 AMAthersys (NASDAQ:ATHX) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 11 at 2:14 AMToughbuilt Industries Inc (TBLT)investing.com - February 26 at 8:48 PMAthersys Inc ATHXQmorningstar.com - February 17 at 10:37 PMAthersys to Sell Most Assets to Healiosmarketwatch.com - January 8 at 11:17 PMAthersys Reports Third Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - November 16 at 10:09 AMAthersys shares migrate to Pink marketplace for broker-to-broker tradingbizjournals.com - October 23 at 4:58 PMAthersys shares delisted by Nasdaq Stock Marketbizjournals.com - October 20 at 8:26 PMAthersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternativesfinance.yahoo.com - October 16 at 7:39 PMAthersys crashes after bankruptcy warningmsn.com - October 10 at 2:34 PMAthersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healiosfinance.yahoo.com - October 10 at 9:33 AMmarketbeat.com - October 10 at 8:26 AMAthersys Licenses its Animal Health Assets to Ardent Animal Healthbusinesswire.com - October 3 at 5:06 PMAthersys Director Jane Wasman Appointed Board Chairfinance.yahoo.com - October 2 at 7:36 PMAthersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blogfinance.yahoo.com - September 26 at 7:41 PMGrant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantationfinance.yahoo.com - September 6 at 3:16 PMIs Athersys Inc (ATHX) Significantly Overvalued?finance.yahoo.com - August 25 at 6:27 PMAthersys Shares Tumble 26% After Pricing Public Offeringmarketwatch.com - August 18 at 6:59 PMWhy Is Athersys (ATHX) Stock Down 36% Today?investorplace.com - August 18 at 11:01 AMAthersys shares slide on pricing $3.5 million stock offeringseekingalpha.com - August 18 at 7:17 AMAthersys, Inc. Announces Pricing of $3.5 Million Public Offeringfinance.yahoo.com - August 18 at 2:17 AMAthersys Reports Second Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - August 16 at 6:34 PMAthersys Appoints Neema Mayhugh, PhD to its Board of Directorsfinance.yahoo.com - August 11 at 5:03 PMAthersys executives foresee catalysts that could ease its financial journeybizjournals.com - August 11 at 2:41 AMAthersys to Host Business Update Conference Call on August 9thbusinesswire.com - July 31 at 2:06 PMAthersys (NASDAQ: ATHX)fool.com - July 30 at 12:18 AMPatient Enrollment Begins in Third and Final Cohorttmcnet.com - June 1 at 8:55 PMPatient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Traumafinance.yahoo.com - June 1 at 8:55 PMAthersys restructures debt with supplier, prioritizing multi-stem for stroke treatmentmsn.com - May 23 at 3:28 PMAthersys Restructures Debt with Supplierfinance.yahoo.com - May 23 at 10:28 AMAthersys cuts quarterly loss as restructuring takes holdbizjournals.com - May 18 at 4:04 PMAthersys Reports First Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - May 18 at 10:47 AMAthersys to Participate in Three Upcoming Conferencesfinance.yahoo.com - May 8 at 11:20 AMAthersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conferencefinance.yahoo.com - May 1 at 10:03 AMAthersys to Participate in The American Society for Neural Therapy and Repair Annual Conferencefinance.yahoo.com - April 21 at 6:06 PMAthersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placementfinance.yahoo.com - April 19 at 8:58 PMAthersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placementfinance.yahoo.com - April 18 at 9:11 AMAthersys to Host Business Update Conference Call on April 20 thbusinesswire.com - April 12 at 10:50 PMAthersys to Host Business Update Conference Call on April 20thfinance.yahoo.com - April 10 at 7:19 PMAthersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlightsfinance.yahoo.com - March 31 at 10:50 PMAthersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlightsfinance.yahoo.com - March 31 at 10:50 PMAthersys Announces Successful Type B Meeting with the FDAfinance.yahoo.com - March 22 at 1:13 PMAthersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussionfinance.yahoo.com - February 14 at 9:28 AMAthersys to Host Business Update Conference Call on February 14thfinance.yahoo.com - February 2 at 10:08 AMAthersys to Participate in International Stroke Conference and BioProcess Internationalfinance.yahoo.com - January 30 at 12:53 PMAthersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in Januaryfinance.yahoo.com - January 11 at 2:38 PMAthersys Provides MultiStem Clinical Updatefinance.yahoo.com - January 9 at 9:20 AMAthersys (ATHX) Stock Plummets to 52-Week Low as Stroke Therapy Fails Mid-Stage Trialthestreet.com - January 4 at 6:46 AMHere’s Why Athersys (ATHX) Stock is Jumping Todaythestreet.com - January 2 at 3:02 PMAthersys, Inc. (NASDAQ:ATHX) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - December 28 at 2:54 PM Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address My next big prediction isn’t a prediction (Ad)I believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in. Click here now to sign up ATHX Media Mentions By Week ATHX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHX News Sentiment▼0.000.62▲Average Medical News Sentiment ATHX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHX Articles This Week▼10▲ATHX Articles Average Week Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TransCode Therapeutics News Today Avalo Therapeutics News Today GRI Bio News Today Galmed Pharmaceuticals News Today Panbela Therapeutics News Today Bellerophon Therapeutics News Today Revelation Biosciences News Today DMK Pharmaceuticals News Today Evofem Biosciences News Today China SXT Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.